Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Financing Activities (2023 - 2025)

Immunocore Holdings' Cash from Financing Activities history spans 3 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 108.32% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $12.4 million, down 96.4%, while the annual FY2025 figure was $12.4 million, 96.4% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $4.3 million at Immunocore Holdings, up from $1.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $396.0 million in Q1 2024 and bottomed at -$51.5 million in Q4 2024.
  • The 3-year median for Cash from Financing Activities is $4.0 million (2025), against an average of $32.5 million.
  • The largest YoY upside for Cash from Financing Activities was 6350.76% in 2024 against a maximum downside of 923.65% in 2024.
  • A 3-year view of Cash from Financing Activities shows it stood at $6.3 million in 2023, then crashed by 923.65% to -$51.5 million in 2024, then skyrocketed by 108.32% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Cash from Financing Activities are $4.3 million (Q4 2025), $1.9 million (Q3 2025), and $3.7 million (Q2 2025).